GSK2330672 + metformin

GSK2330672 + metformin is an investigational combination of two drugs: GSK2330672, a selective small molecule inhibitor of the human ileal bile acid transporter (IBAT, also known as apical sodium-dependent bile acid transporter, ASBT), and metformin, a first-line biguanide antihyperglycemic drug. GSK2330672 is developed to reduce reabsorption of bile acids in the intestine, leading to increased fecal bile acid loss, reduced systemic bile acid levels, and modulation of gastrointestinal and metabolic pathways, with primary indications including reduction of pruritus in primary biliary cholangitis and modulation of glucose metabolism. Metformin acts to decrease hepatic glucose production, improve insulin sensitivity, and increase peripheral glucose uptake. In clinical settings, GSK2330672 and metformin have been investigated for additive or synergistic effects in modulating bile acid physiology and enhancing glucagon-like peptide-1 secretion in people with type 2 diabetes[1][2][3].

Other names

GSK2330672GSK-2330672GSK 2330672